Ignite Creation Date:
2025-12-24 @ 7:13 PM
Ignite Modification Date:
2026-01-01 @ 4:48 PM
Study NCT ID:
NCT04325503
Status:
COMPLETED
Last Update Posted:
2024-04-04
First Post:
2020-03-24
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Neurobiological Drivers of Mobility Resilience: The Dopaminergic System
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2023-08-31', 'type': 'ACTUAL'}}}}, 'interventionBrowseModule': {'meshes': [{'id': 'D002230', 'term': 'Carbidopa'}, {'id': 'C009265', 'term': 'carbidopa, levodopa drug combination'}], 'ancestors': [{'id': 'D008750', 'term': 'Methyldopa'}, {'id': 'D004295', 'term': 'Dihydroxyphenylalanine'}, {'id': 'D002395', 'term': 'Catecholamines'}, {'id': 'D000588', 'term': 'Amines'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D006834', 'term': 'Hydrazines'}, {'id': 'D002396', 'term': 'Catechols'}, {'id': 'D010636', 'term': 'Phenols'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'nbohnen@umich.edu', 'phone': '734-998-8400', 'title': 'Nicolaas Bohnen', 'organization': 'Unversity of Michigan'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'timeFrame': 'Up to 14 days', 'eventGroups': [{'id': 'EG000', 'title': 'Carbidopa and Carbidopa-Levodopa Treatment', 'description': 'All participants treated with 25 mg carbidopa three times daily (TID) and 1.5 pills of 25/100 mg carbidopa-levodopa TID for parkinsonian signs in older persons (standard dosing, frequency for a duration for 1-2 weeks).', 'otherNumAtRisk': 14, 'deathsNumAtRisk': 14, 'otherNumAffected': 8, 'seriousNumAtRisk': 14, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Nausea', 'notes': 'Mild, expected Adverse event (AE).', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Vivid dreams', 'notes': 'Mild, expected AE.', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Mild Changes to Bowel Movement', 'notes': 'Mild, expected AE.', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Mild Nasal Congestion', 'notes': 'Mild, unexpected AE.', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Anxiety', 'notes': 'Mild, expected AE.', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 2, 'numAffected': 1}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Headache', 'notes': 'Mild, expected AE.', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Change in Blood Glucose Level', 'stats': [{'groupId': 'EG000', 'numAtRisk': 14, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Average Gait Speed', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Carbidopa and Carbidopa-Levodopa Treatment', 'description': 'All participants treated with 25 mg carbidopa three times daily (TID) and 1.5 pills of 25/100 mg carbidopa-levodopa TID for parkinsonian signs in older persons (standard dosing, frequency for a duration for 1-2 weeks).'}], 'classes': [{'categories': [{'measurements': [{'value': '0.973', 'spread': '0.123', 'groupId': 'OG000'}]}]}], 'analyses': [{'pValue': '0.015', 'groupIds': ['OG000'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.0905', 'ciLowerLimit': '0.022', 'ciUpperLimit': '0.159', 'pValueComment': 'A priori threshold statistical significance p \\< 0.05', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'Paired samples t-test, df = 9', 'nonInferiorityComment': 'A comparison is not being made between two different treatment groups.'}], 'paramType': 'MEAN', 'timeFrame': '7-13 days after beginning treatment.', 'description': 'Average gait speed as measured using wearable sensors worn during walking tasks. Gait speed is measured in meters per second.', 'unitOfMeasure': 'meters/second', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Gait speed data was missing for one participant due to software error.'}, {'type': 'PRIMARY', 'title': 'Montreal Cognitive Assessment (MoCA)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Carbidopa and Carbidopa-Levodopa Treatment', 'description': 'All participants treated with 25 mg carbidopa three times daily (TID) and 1.5 pills of 25/100 mg carbidopa-levodopa TID for parkinsonian signs in older persons (standard dosing, frequency for a duration for 1-2 weeks).'}], 'classes': [{'categories': [{'measurements': [{'value': '27.44', 'spread': '1.59', 'groupId': 'OG000'}]}]}], 'analyses': [{'pValue': '0.694', 'groupIds': ['OG000'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.333', 'ciLowerLimit': '-1.550', 'ciUpperLimit': '2.216', 'pValueComment': 'A priori threshold for statistical significance is p \\< 0.05', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'Paired samples t-test, df = 8', 'nonInferiorityComment': 'A comparison is not being made between two different treatment groups.'}], 'paramType': 'MEAN', 'timeFrame': '7-13 days after beginning treatment', 'description': 'Cognitive assessment used to evaluate individuals for mild cognitive impairment. Scores range from 0-30. Higher scores indicate better performance.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Two participants did not complete the MoCA during the follow-up visit due to time constraints.'}, {'type': 'PRIMARY', 'title': 'Mini Balance Evaluation Systems Test (Mini-BESTest)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Carbidopa and Carbidopa-Levodopa Treatment', 'description': 'All participants treated with 25 mg carbidopa three times daily (TID) and 1.5 pills of 25/100 mg carbidopa-levodopa TID for parkinsonian signs in older persons (standard dosing, frequency for a duration for 1-2 weeks).'}], 'classes': [{'categories': [{'measurements': [{'value': '22.89', 'spread': '3.951', 'groupId': 'OG000'}]}]}], 'analyses': [{'pValue': '0.103', 'groupIds': ['OG000'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '1.444', 'ciLowerLimit': '-0.363', 'ciUpperLimit': '3.252', 'pValueComment': 'A priori threshold for statistical significance was p \\< 0.05', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'Paired samples t-test, df = 8', 'nonInferiorityComment': 'A comparison is not being made between two different treatment groups.'}], 'paramType': 'MEAN', 'timeFrame': '7-13 days after beginning treatment', 'description': 'The mini-BESTest is a 14-item evaluation of dynamic balance and postural control. It is scored from 0-28, with higher scores indicating better performance.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Testing was not completed for two participants due to time constraints.'}, {'type': 'PRIMARY', 'title': "Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Total", 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Carbidopa and Carbidopa-Levodopa Treatment', 'description': 'All participants treated with 25 mg carbidopa three times daily (TID) and 1.5 pills of 25/100 mg carbidopa-levodopa TID for parkinsonian signs in older persons (standard dosing, frequency for a duration for 1-2 weeks).'}], 'classes': [{'categories': [{'measurements': [{'value': '31.18', 'spread': '10.998', 'groupId': 'OG000'}]}]}], 'analyses': [{'pValue': '0.321', 'groupIds': ['OG000'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '-2.09', 'ciLowerLimit': '-6.554', 'ciUpperLimit': '2.372', 'pValueComment': 'A priori threshold for statistical significance p \\< 0.05', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'Paired samples t-test, df = 10', 'nonInferiorityComment': 'A comparison is not being made between two different treatment groups.'}], 'paramType': 'MEAN', 'timeFrame': '7-13 days after beginning treatment', 'description': 'MDS-UPDRS part III is the motor examination portion of the UPDRS evaluation. Scores range from 0-132, with higher scores indicating greater severity of motor symptoms.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Cognitive Z-score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Carbidopa and Carbidopa-Levodopa Treatment', 'description': 'All participants treated with 25 mg carbidopa three times daily (TID) and 1.5 pills of 25/100 mg carbidopa-levodopa TID for parkinsonian signs in older persons (standard dosing, frequency for a duration for 1-2 weeks).'}], 'classes': [{'categories': [{'measurements': [{'value': '0.271', 'spread': '0.524', 'groupId': 'OG000'}]}]}], 'analyses': [{'pValue': '0.265', 'groupIds': ['OG000'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '0.185', 'ciLowerLimit': '-0.175', 'ciUpperLimit': '0.544', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'Paired samples t-test, df = 7', 'nonInferiorityComment': 'A comparison is not being made between two different treatment groups.'}], 'paramType': 'MEAN', 'timeFrame': '7-13 days after beginning treatment', 'description': 'Composite variable calculated based on the Stroop Color Word Interference test I-IV (assessment of attention) and Delis-Kaplan Executive Function System Trail Making test I-V (assessment of executive function and working memory), adjusted based on normative data for older adults. A z-score of 0 represents the control population mean. Scores above the mean indicate better performance, while scores below the mean indicate poorer performance.', 'unitOfMeasure': 'Z-score', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Data was not collected for 3 participants (one participant did not complete Stroop Color Word Interference tests due to language barrier. One participant did not complete cognitive assessments due to poor vision interfering with test-taking ability. One participant did not complete cognitive testing due to time constraints).'}, {'type': 'PRIMARY', 'title': 'Wechsler Adult Intelligence System Digit Symbol Substitution Test', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Carbidopa and Carbidopa-Levodopa Treatment', 'description': 'All participants treated with 25 mg carbidopa three times daily (TID) and 1.5 pills of 25/100 mg carbidopa-levodopa TID for parkinsonian signs in older persons (standard dosing, frequency for a duration for 1-2 weeks).'}], 'classes': [{'categories': [{'measurements': [{'value': '65.89', 'spread': '20.829', 'groupId': 'OG000'}]}]}], 'analyses': [{'pValue': '0.0270', 'groupIds': ['OG000'], 'paramType': 'Mean Difference (Net)', 'ciNumSides': 'TWO_SIDED', 'ciPctValue': '95', 'paramValue': '8.143', 'ciLowerLimit': '1.296', 'ciUpperLimit': '15.0', 'pValueComment': 'A priori threshold for statistical significance p \\< 0.05', 'statisticalMethod': 't-test, 2 sided', 'nonInferiorityType': 'OTHER', 'statisticalComment': 'Paired samples t-test, df = 6', 'nonInferiorityComment': 'A comparison is not being made between two different treatment groups.'}], 'paramType': 'MEAN', 'timeFrame': '7-13 days after beginning treatment', 'description': 'Evaluation of cognitive functioning in which a participant is given a key of numbers 1-9, each paired with a unique symbol. Below the key, is a series of random numbers which they participant must fill in the corresponding symbol for. They have 120 seconds to complete the task. Participants receive one point for each correct symbol written. Score range from 0-133.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Two participants did not complete testing due to time constraints'}, {'type': 'SECONDARY', 'title': 'Short Activities-specific Balance Confidence Scale Score', 'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Carbidopa and Carbidopa-Levodopa Treatment', 'description': 'All participants treated with 25 mg carbidopa three times daily (TID) and 1.5 pills of 25/100 mg carbidopa-levodopa TID for parkinsonian signs in older persons (standard dosing, frequency for a duration for 1-2 weeks).'}], 'classes': [{'categories': [{'measurements': [{'value': '70.00', 'groupId': 'OG000', 'lowerLimit': '21.67', 'upperLimit': '93.3'}]}]}], 'analyses': [{'pValue': '0.153', 'groupIds': ['OG000'], 'pValueComment': 'A priori threshold for statistical significance p \\< 0.05', 'statisticalMethod': 'Wilcoxon (Mann-Whitney)', 'nonInferiorityType': 'OTHER', 'nonInferiorityComment': 'A comparison is not being made between two different treatment groups.'}], 'paramType': 'MEDIAN', 'timeFrame': '7-13 days after beginning treatment', 'description': 'Participants rate their level of confidence in doing specific activities without losing their balance as a percentage, with 0% indicating they are certain they would lose their balance and 100% indicating that they are certain they can complete the task without losing their balance. Scores on these 6 questions are averaged to determine total sABC score. Scores range from 0-100, with higher scores indicating greater balance confidence.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Carbidopa and Carbidopa-Levodopa Treatment', 'description': 'All participants treated with 25 mg carbidopa three times daily (TID) and 1.5 pills of 25/100 mg carbidopa-levodopa TID for parkinsonian signs in older persons (standard dosing, frequency for a duration for 1-2 weeks).'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '14'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '11'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '3'}]}], 'dropWithdraws': [{'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}]}, {'type': 'PI decided to remove them from trial as they lacked motor symptoms being studied.', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'Treatment', 'description': 'carbidopa and carbidopa-levodopa treatment for parkinsonian signs in older persons using standard dosing, frequency for a duration for 1-2 weeks\n\ncarbidopa: carbidopa and carbidopa-levodopa standard treatment'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'BG000'}]}], 'categories': [{'measurements': [{'value': '73', 'spread': '6.56', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'BG000'}]}], 'categories': [{'title': 'Female', 'measurements': [{'value': '6', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '8', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'BG000'}]}], 'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '14', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'BG000'}]}], 'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'White', 'measurements': [{'value': '14', 'groupId': 'BG000'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'BG000'}]}], 'categories': [{'measurements': [{'value': '14', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Average Gait Speed', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}]}], 'categories': [{'measurements': [{'value': '0.882', 'spread': '0.072', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'description': 'Average gait speed as measured using wearable sensors worn during walking tasks. Gait speed is measured in meters per second.', 'unitOfMeasure': 'meters/second', 'dispersionType': 'STANDARD_DEVIATION', 'populationDescription': 'Average gait speed was not collected for 3 participants because they withdrew (Two participants were withdrawn from the study due to lack of motor symptoms. One participant withdrew from study due to personal time constraints). Gait data was not collected for one participant due to software error.'}, {'title': 'Montreal Cognitive Assessment (MoCA) Score', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'BG000'}]}], 'categories': [{'measurements': [{'value': '26.27', 'spread': '2.76', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'description': 'Cognitive assessment used to evaluate individuals for mild cognitive impairment. Scores range from 0-30. Higher scores indicate better performance.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'STANDARD_DEVIATION', 'populationDescription': 'MoCA was not collected for 3 participants because they withdrew from the study (two participants were withdrawn from the study due to lack of motor symptoms. One participant withdrew from study due to personal time constraints).'}, {'title': 'Mini Balance Evaluation Systems Test (Mini-BESTest)', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '11', 'groupId': 'BG000'}]}], 'categories': [{'measurements': [{'value': '20.09', 'spread': '4.253', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'description': 'The mini-BESTest is a 14-item evaluation of dynamic balance and postural control. It is scored from 0-28, with higher scores indicating better performance.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'STANDARD_DEVIATION', 'populationDescription': 'Mini-BESTest was not collected for 3 participants because they withdrew from the study (two participants were withdrawn from the study due to lack of motor symptoms. One participant withdrew from study due to personal time constraints).'}, {'title': "Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III total", 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'BG000'}]}], 'categories': [{'measurements': [{'value': '29.93', 'spread': '11.672', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'description': 'MDS-UPDRS part III is the motor examination portion of the UPDRS evaluation. Scores range from 0-132, with higher scores indicating greater severity of motor symptoms.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Short Activities-specific Balance Confidence (sABC) scale score', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}]}], 'categories': [{'measurements': [{'value': '76.67', 'groupId': 'BG000', 'lowerLimit': '23.33', 'upperLimit': '95.00'}]}]}], 'paramType': 'MEDIAN', 'description': 'Participants rate their level of confidence in doing specific activities without losing their balance as a percentage, with 0% indicating they are certain they would lose their balance and 100% indicating that they are certain they can complete the task without losing their balance. Scores on these 6 questions are averaged to determine total sABC score. Scores range from 0-100, with higher scores indicating greater balance confidence.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'FULL_RANGE', 'populationDescription': 'sABC was not collected for 3 participants because they withdrew from the study (two participants were withdrawn from the study due to lack of motor symptoms. One participant withdrew from study due to personal time constraints). One participant did not complete questionnaire due to tech error.'}, {'title': 'Cognitive z-score', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}]}], 'categories': [{'measurements': [{'value': '-0.151', 'spread': '0.751', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'description': 'Composite variable calculated based on the Stroop Color Word Interference test I-IV (assessment of attention) and Delis-Kaplan Executive Function System Trail Making test I-V (assessment of executive function and working memory), adjusted based on normative data for older adults. A z-score of 0 represents the control population mean. Scores above the mean indicate better performance, while scores below the mean indicate poorer performance.', 'unitOfMeasure': 'Z-score', 'dispersionType': 'STANDARD_DEVIATION', 'populationDescription': 'Cognitive z-scores were not collected for 3 participants because they withdrew from the study (two participants were withdrawn from the study due to lack of motor symptoms. One participant withdrew from study due to personal time constraints). One participant did not complete all cognitive testing due to language barrier.'}, {'title': 'Wechsler Adult Intelligence Scale Digit Symbol Test Score', 'classes': [{'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'BG000'}]}], 'categories': [{'measurements': [{'value': '54.67', 'spread': '22.472', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'description': 'Evaluation of cognitive functioning in which a participant is given a key of numbers 1-9, each paired with a unique symbol. Below the key, is a series of random numbers which they participant must fill in the corresponding symbol for. They have 120 seconds to complete the task. Participants receive one point for each correct symbol written. Score range from 0-133.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'STANDARD_DEVIATION', 'populationDescription': 'The digit symbol test was not collected for 3 participants because they withdrew from the study (two participants were withdrawn from the study due to lack of motor symptoms. One participant withdrew from study due to personal time constraints). Two participants did not complete testing due to tech error.'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2020-10-21', 'size': 662917, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_001.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2023-07-31T21:29', 'hasProtocol': True}, {'date': '2022-08-11', 'size': 746894, 'label': 'Informed Consent Form', 'hasIcf': True, 'hasSap': False, 'filename': 'ICF_000.pdf', 'typeAbbrev': 'ICF', 'uploadDate': '2022-09-12T12:11', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1', 'PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'OTHER', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 14}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2021-02-08', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-04', 'completionDateStruct': {'date': '2022-06-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-04-02', 'studyFirstSubmitDate': '2020-03-24', 'resultsFirstSubmitDate': '2023-08-09', 'studyFirstSubmitQcDate': '2020-03-25', 'lastUpdatePostDateStruct': {'date': '2024-04-04', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2023-09-05', 'studyFirstPostDateStruct': {'date': '2020-03-27', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2023-09-28', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-06-30', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Average Gait Speed', 'timeFrame': '7-13 days after beginning treatment.', 'description': 'Average gait speed as measured using wearable sensors worn during walking tasks. Gait speed is measured in meters per second.'}, {'measure': 'Montreal Cognitive Assessment (MoCA)', 'timeFrame': '7-13 days after beginning treatment', 'description': 'Cognitive assessment used to evaluate individuals for mild cognitive impairment. Scores range from 0-30. Higher scores indicate better performance.'}, {'measure': 'Mini Balance Evaluation Systems Test (Mini-BESTest)', 'timeFrame': '7-13 days after beginning treatment', 'description': 'The mini-BESTest is a 14-item evaluation of dynamic balance and postural control. It is scored from 0-28, with higher scores indicating better performance.'}, {'measure': "Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III Total", 'timeFrame': '7-13 days after beginning treatment', 'description': 'MDS-UPDRS part III is the motor examination portion of the UPDRS evaluation. Scores range from 0-132, with higher scores indicating greater severity of motor symptoms.'}, {'measure': 'Cognitive Z-score', 'timeFrame': '7-13 days after beginning treatment', 'description': 'Composite variable calculated based on the Stroop Color Word Interference test I-IV (assessment of attention) and Delis-Kaplan Executive Function System Trail Making test I-V (assessment of executive function and working memory), adjusted based on normative data for older adults. A z-score of 0 represents the control population mean. Scores above the mean indicate better performance, while scores below the mean indicate poorer performance.'}, {'measure': 'Wechsler Adult Intelligence System Digit Symbol Substitution Test', 'timeFrame': '7-13 days after beginning treatment', 'description': 'Evaluation of cognitive functioning in which a participant is given a key of numbers 1-9, each paired with a unique symbol. Below the key, is a series of random numbers which they participant must fill in the corresponding symbol for. They have 120 seconds to complete the task. Participants receive one point for each correct symbol written. Score range from 0-133.'}], 'secondaryOutcomes': [{'measure': 'Short Activities-specific Balance Confidence Scale Score', 'timeFrame': '7-13 days after beginning treatment', 'description': 'Participants rate their level of confidence in doing specific activities without losing their balance as a percentage, with 0% indicating they are certain they would lose their balance and 100% indicating that they are certain they can complete the task without losing their balance. Scores on these 6 questions are averaged to determine total sABC score. Scores range from 0-100, with higher scores indicating greater balance confidence.'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['slow gait', 'Parkinsonian signs'], 'conditions': ['Parkinsonian Signs in Older Persons']}, 'descriptionModule': {'briefSummary': "Walking with age becomes both slower and less 'automated', requiring more attention and brain resources. As a result, older adults have a greater risk of negative outcomes and falls. There is an urgent need to identify factors that can help compensate for these harmful factors and reduce walking impairments, as there are currently no effective treatments available. Investigators have recently discovered that \\~20% of older adults maintain fast walking speed even in the presence of small blood vessel brain changes and leg problems, thus appearing to be protected against these harmful factors. The investigators work suggests that the brain dopamine (DA) system may be a source of this protective capacity. Investigators have also shown that lower levels of dopamine are associated with slow walking. Investigators will be investigating the role of dopamine on slow walking and other parkinsonian signs using detailed clinical assessment, assessment of dopamine activity, and clinical interventions.", 'detailedDescription': "Walking with age becomes both slower and less 'automated', requiring more attention and prefrontal resources. As a result older adults have a greater risk of adverse mobility outcomes and falls. Walking disturbances in the elderly have been linked to changes in both cerebral, in particular small vessel disease (cSVD), and peripheral systems. There is an urgent need to identify factors that can help compensate for these harmful factors and reduce walking impairments, as there are currently no effective treatments available. Although effective mobility is the end result of the functional capacity of both central and peripheral systems, the brain's unique modulatory and adaptive capacity may provide clues for novel interventions. For example, investigators have recently discovered that \\~20% of older adults maintain fast walking speed even in the presence of age related cSVD and peripheral system impairments, thus appearing resilient to these harmful factors. The investigators work suggests that the nigrostriatal dopamine (DA) system may be a source of this resilience. As investigators recent findings suggest, DA neurotransmission positively predicts walking speed; it also attenuates the negative effects of age related cSVD and peripheral system impairments on walking speed. These findings are consistent with post-mortem evidence that a combination of loss of nigral DA neurons and cSVD best predict age-related walking impairment. The nigrostriatal DA system plays a critical role in motor control; nigrostriatal. DA neurotransmission regulates the automated execution of overlearned motor tasks via its connections with sensorimotor cortical and subcortical areas.\n\nThe investigators hypothesize that higher nigrostriatal DA neurotransmission drives resilience to cSVD and peripheral system impairments, via higher connectivity of sensorimotor networks, thus increasing automaticity of walking and reducing prefrontal engagement while walking. Unlike cSVD and brain structural impairments, DA neurotransmission is potentially modifiable, thereby offering novel approaches to treat non-resilient elderly in a targeted fashion. This translational pilot study will use a biomechanistic target engagement study in older adults with slow walking and/or other parkinsonian signs.\n\nThe study will include elderly men and women age 60 or older with evidence of mild parkinsonian signs (MPS, or slow gait (\\< 1m/s)) and/or additional cSVD on brain MRI."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '60 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Age 60 or older (M/F)\n2. Evidence of mild parkinsonian signs (incl. slow gait (\\< 1m/s))\n\nExclusion Criteria:\n\n1. Presence of clinically significant degenerative joint disease and/or neuropathy interfering with proper assessment of the motor UPDRS exam.\n2. Presence of significant dementia.\n3. Evidence of a large vessel stroke in a clinically relevant area (cerebral cortex, basal ganglia, thalamus) or mass lesion on structural brain imaging (MRI).\n4. Participants in whom magnetic resonance imaging (MRI) is contraindicated including, but not limited to, those with a pacemaker, presence of metallic fragments near the eyes or spinal cord, or cochlear implant.\n5. Severe claustrophobia precluding neuroimaging procedures.\n6. Hypersensitivity to the carbidopa, levodopa, and tablet components.\n7. Any other medical history determined by investigators to preclude safe participation.'}, 'identificationModule': {'nctId': 'NCT04325503', 'acronym': 'RES', 'briefTitle': 'Neurobiological Drivers of Mobility Resilience: The Dopaminergic System', 'organization': {'class': 'OTHER', 'fullName': 'University of Michigan'}, 'officialTitle': 'Neurobiological Drivers of Mobility Resilience: The Dopaminergic System', 'orgStudyIdInfo': {'id': 'HUM00156490'}, 'secondaryIdInfos': [{'id': '5U01AG061393-05', 'link': 'https://reporter.nih.gov/quickSearch/5U01AG061393-05', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Treatment', 'description': 'carbidopa and carbidopa-levodopa treatment for parkinsonian signs in older persons using standard dosing, frequency for a duration for 1-2 weeks', 'interventionNames': ['Drug: carbidopa']}], 'interventions': [{'name': 'carbidopa', 'type': 'DRUG', 'otherNames': ['carbidopa-levodopa'], 'description': 'carbidopa and carbidopa-levodopa standard treatment', 'armGroupLabels': ['Treatment']}]}, 'contactsLocationsModule': {'locations': [{'zip': '48105', 'city': 'Ann Arbor', 'state': 'Michigan', 'country': 'United States', 'facility': 'Functional Neuroimaging, Cognitive, and Mobility Lab, University of Michigan', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}], 'overallOfficials': [{'name': 'Nicolaas Bohnen, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Michigan'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO', 'description': 'Results will be provided in publications'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Michigan', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Institute on Aging (NIA)', 'class': 'NIH'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator', 'investigatorFullName': 'Nicolaas Bohnen, MD, PhD', 'investigatorAffiliation': 'University of Michigan'}}}}